Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, January 2026 JPGN

Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026

Key:

Complete
Failed
Available
Locked
Learner Notification and Instructions: Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
Open to download resource.
Open to download resource. Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
You must register to access.
Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
Open to download resource.
Open to download resource. Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
You must register to access.
Post Test: Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
3 Questions  |  Unlimited attempts  |  2/3 points to pass
3 Questions  |  Unlimited attempts  |  2/3 points to pass Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
You must register to access.
Post-Webinar Evaluation: Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
14 Questions
14 Questions Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
You must register to access.
Certificate: Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
1.00 credit  |  Certificate available
1.00 credit  |  Certificate available Glecaprevir/pibrentasvir in patients aged 3–17 years with chronic hepatitis C: Real‐life data from the POLAC project, JPGN January 2026
You must register to access.